Difference between revisions of "Team:USP UNIFESP-Brazil/Parts"
MiguelCroce (Talk | contribs) |
MiguelCroce (Talk | contribs) |
||
| Line 96: | Line 96: | ||
<p class="black">The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.</p> | <p class="black">The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.</p> | ||
</div> | </div> | ||
| − | </div> | + | </div> |
| + | </div> | ||
Revision as of 21:04, 18 October 2016
AlgAranha Team USP-UNIFESP BRASIL
Part Table
The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.
Our major contribution of a Basic Part for the iGEM community is a BioBrick coding for the catalytic protein domain of lysostaphin (BBa_K2136002).This is an antibiotic peptide domain which can be used by future teams in the development of projects fighting antibiotic resistance or working with dinamics of Staphyloccoccus populations.
Our favourite composite part was the 5' 5' cassete for Chlamydomonas transgenic expression(BBa_K2136010). We validated it through a series of measurements which show the production and secretion of mCherry protein by Chlamydomonas. A detailed descriptions is available in our Proof of concept page.
Part Table
The protein structure of spider silk is composed of two constant terminal domains and a variable middle structural domain. Our design uses the substitution of this middle domain by a protein of interest, as used by Team:UCLA in 2014. In our case, we are using enzybiotics.
